<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809740</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-300004654</org_study_id>
    <nct_id>NCT04809740</nct_id>
  </id_info>
  <brief_title>Evaluating the Implementation and Impact of Navigator-delivered ePRO System</brief_title>
  <official_title>Evaluating the Implementation and Impact of Navigator-delivered ePRO Home Symptom Monitoring and Management</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alabama at Birmingham</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of South Alabama</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Alabama at Birmingham</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1) Evaluate implementation of navigator-delivered Home ePRO for all cancer patients across&#xD;
      multiple practice sites; 2) examine the barriers, facilitators, and implementation strategies&#xD;
      used in implementing navigator-delivered Home ePRO; and 3) assess the impact of Home ePRO on&#xD;
      clinical and utilization outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized controlled trials by Basch (collaborator) and colleagues demonstrated that weekly&#xD;
      electronic home-based PRO symptom monitoring with automated alerts to clinicians (Home ePRO)&#xD;
      in cancer patients was associated with reduced healthcare utilization, improved quality of&#xD;
      life, and increased overall survival. However, these trials were administered using&#xD;
      infrastructure supported by research funding. A knowledge gap remains about optimal&#xD;
      implementation strategies for and effectiveness of Home ePROs in real-world settings. To&#xD;
      address this gap, investigators from two institutions will conduct a large-scale&#xD;
      population-based implementation of an evidence-based Home ePRO intervention for all adult&#xD;
      cancer patients receiving chemotherapy, including vulnerable populations such as African&#xD;
      Americans, rural residents, and socioeconomically disadvantaged individuals. This&#xD;
      implementation will leverage infrastructure from Medicare's payment reform projects (Oncology&#xD;
      Care Model, Oncology Care First Model), which require and financially support patient&#xD;
      navigators, a natural workforce for Home ePRO implementation. The investigators' hypothesis&#xD;
      is that the deployed implementation strategies will result in successful navigator-delivered&#xD;
      Home ePRO, which will improve both patient and health system outcomes. Using the Consolidated&#xD;
      Framework for Implementation Research (CFIR), this hypothesis will be tested using a hybrid&#xD;
      type 2 design with three specific aims: 1) evaluate implementation of navigator-delivered&#xD;
      Home ePRO for all cancer patients across multiple practice sites; 2) examine the barriers,&#xD;
      facilitators, and implementation strategies used in implementing navigator-delivered Home&#xD;
      ePRO; and 3) assess the impact of Home ePRO on clinical and utilization outcomes. In Aim 1,&#xD;
      Home ePRO will be evaluated using implementation outcomes (service penetrance, provider&#xD;
      adoption/penetration, intervention fidelity). In Aim 2, the investigators will gauge patient&#xD;
      and healthcare team perceptions of barriers, facilitators of navigator-led Home ePRO,&#xD;
      implementation strategies used to address these barriers, implementation strategy fidelity,&#xD;
      and perception of implementation strategy ability to address barriers using an iterative&#xD;
      qualitative analysis. In Aim 3, patient-level outcomes (functional status, distress,&#xD;
      depression, healthcare utilization, cost, survival) will be evaluated using real-world data&#xD;
      sources. The project is innovative because it will be the first study to evaluate real-world&#xD;
      implementation of navigator-led Home ePRO for all cancer patients receiving chemotherapy, an&#xD;
      approach that is both immediately scalable and sustainable within value-based payment models.&#xD;
      The proposed research is significant because it is expected to demonstrate successful&#xD;
      implementation of navigator-delivered Home ePRO and effectiveness of the ePRO intervention on&#xD;
      diverse patient populations. Furthermore, the project will generate an implementation&#xD;
      blueprint of successful implementation strategies that can be easily applied to other&#xD;
      patient-reported outcomes, with the potential to positively impact patient care as health&#xD;
      care transitions to a value-based system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 4, 2021</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Implementation</measure>
    <time_frame>5 years</time_frame>
    <description>To evaluate the implementation and outcomes associated with standard-of-care Home ePRO</description>
  </primary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">50375</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Patient Group 1</arm_group_label>
    <description>Initial chart review - Component 2 - 15,000 Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Providers Group 1</arm_group_label>
    <description>Initial chart review-Component 2 - 300 Providers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient Group 2</arm_group_label>
    <description>Initial chart review-Component 3 - 35,000 Patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Providers Group 2</arm_group_label>
    <description>Provider Interview-Component 4 - 15 Providers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient Group 3</arm_group_label>
    <description>Patient Interview-Component 4 - 15-60 Patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>evaluate implementation of navigator-delivered Home ePRO for all cancer patients</intervention_name>
    <description>evaluate implementation of navigator-delivered Home ePRO for all cancer patients across multiple practice sites; 2) examine the barriers, facilitators, and implementation strategies used in implementing navigator-delivered Home ePRO; and 3) assess the impact of Home ePRO on clinical and utilization outcomes</description>
    <arm_group_label>Patient Group 1</arm_group_label>
    <arm_group_label>Patient Group 2</arm_group_label>
    <arm_group_label>Patient Group 3</arm_group_label>
    <arm_group_label>Providers Group 1</arm_group_label>
    <arm_group_label>Providers Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult cancer patients receiving chemotherapy (traditional chemotherapy, immunotherapy,&#xD;
        targeted therapy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patient Group 1:&#xD;
&#xD;
          -  Age ≥18&#xD;
&#xD;
          -  Cancer patients at participating institution&#xD;
&#xD;
          -  Receipt of chemotherapy, targeted therapy, and immunotherapy at participating&#xD;
             institution from 2019-2026.&#xD;
&#xD;
        Patient Group 2:&#xD;
&#xD;
          -  Age ≥18&#xD;
&#xD;
          -  Patients with cancer&#xD;
&#xD;
          -  Receipt of chemotherapy, targeted therapy, and immunotherapy at a participating&#xD;
             institution from 2012-2026.&#xD;
&#xD;
        Patient Group 3:&#xD;
&#xD;
          -  Age ≥18&#xD;
&#xD;
          -  Receipt of chemotherapy, targeted therapy, and immunotherapy at either UAB or MCI.&#xD;
&#xD;
        Provider Group 1:&#xD;
&#xD;
        - Providers participating in standard-of-care Home ePRO implementation (physicians, nurses,&#xD;
        nurse navigators, and lay navigators) from 2019-2026.&#xD;
&#xD;
        Provider Group 2:&#xD;
&#xD;
        - Providers participating in standard-of-care Home ePRO implementation (physicians, nurses,&#xD;
        nurse navigators, and lay navigators)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient Group 1,2,3 - Second opinion only at participating institution.&#xD;
&#xD;
          -  Provider Group - none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stacey A Ingram, MEd</last_name>
    <phone>205-934-6287</phone>
    <email>saadewakun@uabmc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valerie M Lawhon, BS</last_name>
    <phone>205-934-9652</phone>
    <email>vlawhon@uabmc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey A Adewakun, MEd</last_name>
      <phone>205-934-5287</phone>
      <email>saadewakun@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Gabrielle B Rocque, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey A Ingram, MEd</last_name>
      <phone>205-934-5287</phone>
      <email>saadewakun@uabmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 10, 2020</study_first_submitted>
  <study_first_submitted_qc>March 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>May 10, 2021</last_update_submitted>
  <last_update_submitted_qc>May 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alabama at Birmingham</investigator_affiliation>
    <investigator_full_name>Gabrielle Rocque</investigator_full_name>
    <investigator_title>Associate Professor of Medicine, Division of Hematology &amp; Oncology; Division of Gerontology, Geriatrics, &amp; Palliative Care</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

